Immunotherapy treatments approved for stage 2 (II) non-small cell lung cancer
If you have stage 2 (II) lung cancer that is treatable by surgery, you may receive immunotherapy and chemotherapy prior to your surgery. This is called neoadjuvant treatment and is meant to increase the efficacy of the surgery.
APPROVED THERAPY:
-
Imfinzi (durvalumab, a PD-L1 inhibitor) – approved in combination with chemotherapy for stage 2 (II) NSCLC patients whose cancer can be removed by surgery and on its own after surgery. The cancer must not have EGFR or ALK mutations.
-
Opdivo (nivolumab, a PD-1 Inhibitor) – approved in combination with chemotherapy before surgery and alone after surgery for people with stage 2 (II) NSCLC that can be removed by surgery.
-
Tecentriq (atezolizumab, a PD-L1 Inhibitor) – approved after adjuvant chemotherapy for stage 2 (II) NSCLC patients with >1% PD-L1 whose cancer can be removed by surgery.